DUBLIN--(BUSINESS WIRE)--The "Pharmacovigilance Market Size, Share & Trends Analysis Report by Product Life Cycle, by Service Provider, by Type, by Process Flow, by Therapeutic Area, by End-use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
The global pharmacovigilance market size is expected to reach USD 17.36 billion by 2030 and is expected to expand at a CAGR of 10.5% from 2022 to 2030.
Increasing incidence of Adverse Drug Reactions (ADRs) is the key growth driver. ADR imposes a substantial burden on healthcare systems and is one of the prominent causes of morbidity in developed countries. According to the National Center for Biotechnology Information (NCBI), approximately 5% of total hospitalizations in Europe each year are due to ADR. Pharmacovigilance services play an integral role in this clinical trial phase by assisting manufacturers in identifying adverse effects associated with the drug.
COVID-19 has undoubtedly thrown up numerous challenges as well as opportunities for pharmacovigilance service providers. Various companies are developing innovative platforms to gain a competitive edge. For instance, in December 2020, ArisGlobal and EVERSANA declared a strategic partnership to digitally transform end-to-end pharmacovigilance services globally.
The community involved in a PV procedure has been quick to respond to the pandemic. Some companies are using big data analytics against COVID-19. Thus, this refers to the in-depth analysis of data from multiple sources. In April 2020, Saama Technologies offered its Life Science Analytics Cloud technology platform to support the consortium creation. The purpose is to fetch data from both current and future studies to slash the time required to discover a treatment by as much as 50%. Life Science Analytics Cloud is an artificial intelligence-powered platform. This represents the scope for future developments in this market.
According to the World Health Organization's (WHO) report on pharmaceutical consumption, chronic disease medications accounted for the larger proportion of the total volume of drug consumption in non-hospital setups. Hence, there has been a significant rise in the number of medicines made available to healthcare consumers. The rising demand for drugs has significantly heightened the need for the development of novel therapeutics via extensive clinical trials, which is expected to serve this market with lucrative opportunities.
Moreover, leading pharma companies in developed countries are focusing on outsourcing PV services to reduce costs and minimize operational expenses. This is anticipated to serve as an opportunity for contact research organizations in developing regions to gain more revenue share. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for pharmacovigilance services during the forecast period.
The companies operating in the market are undertaking strategic initiatives, such as collaborations with the PV service providers, to gain access to medical information and to manage PV workflows. For instance, In October 2021, The Whiteboard, an academy for training specialists in the clinical trials and drug development field, proclaimed a partnership with Oviya MedSafe, a worldwide drug safety service, and pharmacovigilance consulting corporation.
Similarly, in September 2019, Accenture collaborated with Bayer to implement the company's INTIENT Clinical platform to simplify and speed its drug development processes, thereby widening its business. The company collaborated with BioCelebrate in the past to develop a platform for aggregating and analyzing clinical information for improved drug developing efficiency, thus enhancing its R&D capabilities. Such initiatives help companies maintain their position and thereby support market growth.
Pharmacovigilance Market Report Highlights
- On the basis of a product life cycle, the phase IV segment held a dominant revenue share of over 75.0% in 2021 owing to the extensive post-marketing surveillance of pharmaceuticals and an increasing number of ADR incidences in the market
- By service provider, contract outsourcing held a significant revenue share of over 55.0% in 2021 owing to the shift in the focus of pharmaceutical companies to outsourcing services to reduce operational cost
- Based on type, spontaneous reporting held the largest revenue share in 2021 due to its wide application in pharmacovigilance and benefits such as easy simulation of data sets for better drug comparison
- The biotechnology companies end-use segment is anticipated to exhibit a lucrative CAGR over the forecast period owing to the increasing R&D for the development of novel biologics
- Asia Pacific is anticipated to expand at the fastest CAGR of 12.1% over the forecast period. This is attributed to the availability of low-cost labor and the rising number of outsourcing companies in this region
- Industry participants are focusing on increasing R&D activities to develop better pharmacovigilance services. Moreover, companies are adopting strategies including new product launches, collaborations, and mergers & acquisitions to gain a competitive advantage
Pharmacovigilance Market Dynamics
Market driver analysis
- Growing drug consumption and drug development rates
- Increasing incidence of ADR and drug toxicity
- Increasing trend of outsourcing pharmacovigilance services
- Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
- Increasing Regulatory Burden on Manufacturers
- Introduction of technologically advanced software services
- Constantly rising investment in R&D by healthcare companies
- Partnerships and collaborations between market players
Market restraint analysis
- Shortage of skilled labor
- Expensive technology for small and mid-sized players
- Lack of recognition
- Scarcity of integration standards
Industry Challenges
Pharmacovigilance Market Analysis Tools: Porters
SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
Value Chain Analysis
- Pre-clinical
- Clinical
- PMA
Mapping of Life Cycle Against Service Offering And Their Demand
Regulatory Framework
Pharmacovigilance: Organization Structure Introduction
Pricing Models
- Drug Safety Budget Allocation By Activities
- By Development phase
- By Therapeutic area
- Pricing Level
- Case processing
- ADR Reporting
- Medical writing
- Drug safety management
Technology Timeline Overview
- Changing Technology & Adoption
- Social Media
- Literature screening
- Automation and AI
- Big data analytics in PV
COVID-19 Impact Analysis
COVID-19 Outbreak
- Challenges for safety reporting activities
Demand Analysis
- Product Pipeline Analysis, by Stage for COVID-19
Recent Developments & Strategic Outcomes
- Regulatory requirements/changes due to covid-19
- Strategies implemented by companies
- IQVIA
- PARAXEL International Corporation
- Bioclinica
- Pharmaceutical Product Development (PPD)
- IBM Corporation
- ICON, plc
- PRA Health Sciences
- Covance Inc.
- ArisGlobal
- Linical Accelovance
- Laboratory Corporation of America Holdings
Company Profiles
- Accenture
- Clinquest Group B.V. (Linical Americas)
- IQVIA
- Cognizant
- Laboratory Corporation of America Holdings
- IBM Corporation
- ArisGlobal
- ICON Plc.
- Capgemini
- ITClinical
- TAKE Solutions
- PAREXEL International Corporation
- BioClinica, Inc.
- Wipro Limited
- UNITED BIOSOURCE CORPORATION
- FMD K&L
For more information about this report visit https://www.researchandmarkets.com/r/5u8auc
